- AbbVie targets psychedelic-based depression drug market with $1.2 billion deal Reuters
- AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline PR Newswire
- AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug Yahoo Finance
- AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion statnews.com
- AbbVie to buy psychedelic drug from partner Gilgamesh Endpoints News
Source link
